"Aimovig provides patients with a novel option for reducing the number of days with migraine," said Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "We need new treatments for this painful and often debilitating condition."

Patients often describe migraine headache pain as an intense pulsing or throbbing pain in one area of the head. Additional symptoms include nausea and/or vomiting and sensitivity to light and sound. Approximately one-third of affected individuals can predict the onset of a migraine because it is preceded by an aura—transient sensory or visual disturbances that appear as flashing lights, zig-zag lines or a temporary loss of vision. People with migraine tend to have recurring attacks triggered by a number of different factors, including stress, hormonal changes, bright or flashing lights, lack of food or sleep and diet. Migraine is three times more common in women than in men and affects more than 10 percent of people worldwide.

The effectiveness of Aimovig for the preventive treatment of migraine was evaluated in three clinical trials. The first study included 955 participants with a history of episodic migraine and compared Aimovig to placebo. Over the course of six months, Aimovig-treated patients experienced, on average, one to two fewer monthly migraine days than those on placebo. The second study included 577 patients with a history of episodic migraine and compared Aimovig to placeb.
Over the course of three months, Aimovig-treated patients experienced, on average, one fewer migraine day per month than those on placebo. The third study evaluated 667 patients with a history of chronic migraine and compared Aimovig to placebo. In that study, over the course of three months, patients treated with Aimovig experienced, on average, 2 ½ fewer monthly migraine days than those receiving placebo.

The most common side effects that patients in the clinical trials reported were injection site reactions and constipation.

The FDA granted the approval of Aimovig to Amgen Inc.

To receive daily emails from Breaking Christian News to your inbox CLICK HERE

Ancient Beams Offer New Evidence of the First Temple's Destruction

New Visa Restrictions Target Left-Wing Terrorists and Extremists

Trump Ramps up Military Pressure on Iran's Regime, Targeting Area Near Pickaxe Mountain Nuclear Site

Epic Fail: Mamdani Finally Makes Humiliating Admission About His Threat to Arrest Netanyahu

How China Made and Shipped Fake Driver's Licenses to Tamper With the 2020 Election

Andy Biggs Dominates Arizona Race

DSA Unveils Platform Calling for Abolishing the Senate, Presidency, and Supreme Court

6,600 Non-Citizens Registered to Vote in NJ Due to 'Software Error,' Dem Gov. Sherrill Admits

Justin Bieber Used the Biggest Stage Ever to Worship God with 'Everything Hallelujah' at World Cup Final

Trump Education Department Defends Homeschool Parents from Hateful, Woke Podcasters

House Committee Approves Bill Allowing Victims of 'Trans' Drugs, Surgeries to Sue

Major Teachers Union That Funds Democrats Endorses 'Gender-Affirming Care' Amid Backlash to Transgender 'Medicine'

Oregon's Troubling Transgender Story; Why Are They Pumping Minors Full of Puberty Blockers?

Trump Admin Launches 'Largest Denaturalization Effort Ever' Against Child Molesters and Scammers

Report: Iran Moves Nuclear Centrifuges Underground as Houthis Threaten US Coalition, Red Sea Shipping

State Department Issues Worldwide Caution for Traveling US Citizens

'Resurrection of the Christ' Writer Reveals Mel Gibson's Spiritual Warfare Warning about the 'Passion' Sequel

Second Family Welcomes Their New Baby Boy

FDA: That Recalled Lettuce from Taylor Fresh Farms Turned Out to Be a 'False Positive' for Cyclospora

About Those Burn Bags President Trump Mentioned in His Address to the Nation